TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model
暂无分享,去创建一个
T. Helleday | V. Gorgoulis | D. Heymann | U. W. Berglund | T. Pham | B. Ory | S. Battaglia | T. Quillard | I. Pateras | F. Lamoureux | H. Brown | C. Charrier | M. Baud’huin | Brice Moukengué
[1] Wen-en Zhao,et al. Potent and specific MTH1 inhibitors targeting gastric cancer , 2019, Cell Death & Disease.
[2] Zhen Wang,et al. Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma , 2019, Journal of bone oncology.
[3] T. Helleday,et al. MTH1 promotes mitotic progression to avoid oxidative DNA damage in cancer cells , 2019, bioRxiv.
[4] I. B. Borel Rinkes,et al. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures , 2019, Scientific Reports.
[5] G. Iliakis,et al. The presumed MTH1-inhibitor TH588 sensitizes colorectal carcinoma cells to ionizing radiation in hypoxia , 2018, BMC Cancer.
[6] M. Kruszewski,et al. hMTH1 is required for maintaining migration and invasion potential of human thyroid cancer cells. , 2018, DNA repair.
[7] M. Heymann,et al. Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy , 2018, Journal of bone oncology.
[8] K. Jang,et al. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma , 2018, Journal of Experimental & Clinical Cancer Research.
[9] F. Gao,et al. Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species , 2018, Anti-cancer drugs.
[10] M. Heymann,et al. Biology of Bone Sarcomas and New Therapeutic Developments , 2017, Calcified Tissue International.
[11] Steven S. Foster,et al. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good? , 2017, bioRxiv.
[12] Haocai Chang,et al. Induction of reactive oxygen species: an emerging approach for cancer therapy , 2017, Apoptosis.
[13] G. Chrousos,et al. Genome Instability and γH2AX , 2017, International journal of molecular sciences.
[14] A. Bitto,et al. Oxidative Stress: Harms and Benefits for Human Health , 2017, Oxidative medicine and cellular longevity.
[15] Andreas Höglund,et al. Glioblastoma and glioblastoma stem cells are dependent on functional MTH1 , 2017, Oncotarget.
[16] T. Cotter,et al. ROS signalling in the biology of cancer. , 2017, Seminars in cell & developmental biology.
[17] Y. Nakabeppu,et al. MTH1 as a nucleotide pool sanitizing enzyme: Friend or foe?☆ , 2017, Free radical biology & medicine.
[18] P. Rai,et al. MTH1 as a Chemotherapeutic Target: The Elephant in the Room , 2017, Cancers.
[19] Y. Kallberg,et al. Validation and development of MTH1 inhibitors for treatment of cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Makoto Muroi,et al. Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival , 2016, Scientific Reports.
[21] Graeme Walker,et al. Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival. , 2016, Journal of medicinal chemistry.
[22] T. Helleday,et al. Addiction to MTH1 protein results in intense expression in human breast cancer tissue as measured by liquid chromatography-isotope-dilution tandem mass spectrometry. , 2015, DNA repair.
[23] J. Lee. Osteosarcoma in Korean children and adolescents , 2015, Korean journal of pediatrics.
[24] Jiexiong Feng,et al. Review of the molecular pathogenesis of osteosarcoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[25] T. Helleday. Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival. , 2014 .
[26] Richard Svensson,et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool , 2014, Nature.
[27] G. Superti-Furga,et al. Stereospecific targeting of MTH1 by (S)-crizotinib as anticancer strategy , 2014, Nature.
[28] P. Nordlund,et al. Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay , 2013, Science.
[29] G. Giaever,et al. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. , 2013, Chemistry & biology.
[30] R. Weinberg,et al. Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence , 2011, Oncogene.
[31] K. Sakumi,et al. Programmed cell death triggered by nucleotide pool damage and its prevention by MutT homolog-1 (MTH1) with oxidized purine nucleoside triphosphatase. , 2010, Mutation research.
[32] B. Tudek,et al. Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. , 2010, Mutagenesis.
[33] P. Storz,et al. Reactive oxygen species in cancer , 2010, Free radical research.
[34] R. Weinberg,et al. Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence , 2009, Proceedings of the National Academy of Sciences.
[35] F. Gouin,et al. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies , 2007, Expert review of anticancer therapy.
[36] F. Mseeh,et al. Identification of potent and selective MTH1 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[37] P. Storz. Reactive oxygen species in tumor progression. , 2005, Frontiers in bioscience : a journal and virtual library.
[38] E. Rogakou,et al. Histone H2A variants H2AX and H2AZ. , 2002, Current opinion in genetics & development.
[39] Michael M. Murphy,et al. ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks* , 2001, The Journal of Biological Chemistry.
[40] T Ishikawa,et al. Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] H. Kamiya,et al. Human MTH1 protein hydrolyzes the oxidized ribonucleotide, 2-hydroxy-ATP. , 2001, Nucleic acids research.
[42] G. Rosen,et al. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma , 1976, Cancer.
[43] S. Farber,et al. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. , 1949, Blood.
[44] M. Wintrobe. Nitrogen mustard therapy. , 1948, The American journal of medicine.
[45] L. Goodman,et al. NITROGEN MUSTARD THERAPY: Use of Methyl-Bis(Beta-Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders , 1946 .
[46] J. Bradner,et al. Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. , 2017, Bone.
[47] R. Patel,et al. Direct detection of 8-oxodeoxyguanosine and 8-oxoguanine by avidin and its analogues. , 1998, Analytical biochemistry.